Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In the long and intensive search for effective treatments to counteract the toxicity of the chemical warfare (CW) agent sulphur mustard (H; bis(2-chloroethyl) sulphide), the most auspicious and consistent results have been obtained with the drug N-acetylcysteine (NAC), particularly with respect to its therapeutic use against the effects of inhaled H. It is a synthetic cysteine derivative that has been used in a wide variety of clinical applications for decades and a wealth of information exists on its safety and protective properties against a broad range of toxicants and disease states. Its primary mechanism of action is as a pro-drug for the synthesis of the antioxidant glutathione (GSH), particularly in those circumstances where oxidative stress has exhausted intracellular GSH stores. It impacts a number of pathways either directly or through its GSH-related antioxidant and anti-inflammatory properties, which make it a prime candidate as a potential treatment for the wide range of deleterious cellular effects that H is acknowledged to cause in exposed individuals. This report reviews the available literature on the protection afforded by NAC against the toxicity of H in a variety of model systems, including its efficacy in treating the long-term chronic lung effects of H that have been demonstrated in Iranian veterans exposed during the Iran-Iraq War (1980–1988). Although there is overwhelming evidence supporting this drug as a potential medical countermeasure against this CW agent, there is a requirement for carefully controlled clinical trials to determine the safety, efficacy and optimal NAC dosage regimens for the treatment of inhaled H.

1. Introduction

The vesicant sulphur mustard (H; bis(2-chloroethyl) sulphide, Figs. 1 and 2) was first used as a chemical warfare (CW) agent during the First World War. Although only introduced in July of 1917 by the Germans against British troops at Ypres, Belgium, by the end of the war both sides of the conflict had used it extensively and the majority of British (77.5%), and American (75.0%) chemical casualties were attributed to this agent [pp. 129 [1]]. It has been used subsequently in a number of smaller conflicts [2–4], culminating in the Iran/Iraq War (1980–1988) where over 100,000 Iranian and Iraqi-Kurdish civilians and soldiers were exposed to this chemical agent [5]. Almost thirty years later, evidence of H use by non-state actors during the Syrian Civil War has also been reported [6–10].

The primary target organs of H exposure include the skin, eyes, mucous membranes and respiratory tract (Fig. 3), and the clinical and histopathological features of acute exposure have been well studied and reviewed [2–4,11–18]. Skin lesions (Fig. 4) can be produced by either vapour or liquid H exposure, with the injury severity dependent on dose, temperature, humidity, skin moisture and regional skin thickness. At low exposures, erythema is produced after a highly variable latent period. At higher exposures, this latent period becomes shorter and the injury progresses to small vesicles that may consolidate to larger blisters. At very high liquid doses, necrosis of the skin may occur with no blistering, or a ring of blisters surrounding a necrotic zone may be produced [3,4]. Due to the antimitotic nature of H, these lesions are very slow to heal, often with hyper- and/or hypopigmentation of the skin (Fig. 4). Symptoms produced by H vapour or aerosol inhalation are concentration-dependent and include pain or discomfort after a variable latent period of 2–16 h. Larger exposures cause damage to the larynx and upper airways causing cough after shorter time periods. Very large vapour exposures cause extensive damage to the terminal airways, resulting in severe cough, dyspnea, haemorrhage into the alveoli and purulent sputum. Respiratory infections are common and are a major cause of death due to H exposure [3,4,13,16].

The above two routes of exposure represent the major sources of H distribution into the systemic circulation, either directly, or in the case of skin exposure, also indirectly and more slowly through H depots formed in the lipid components of the skin [19,20]. Dermal application of HCl labeled butyl 2-chloroethyl sulfide (BCS) to rats resulted in the distribution of this H simulant to several different organs, including brain within 1 h [21], while chemical analysis of tissues from an Iranian fatality due to H exposure, detected significant quantities of H in lipid-rich organs including (in mg H/kg tissue wet weight) fat (15.1), brain (10.7), skin (8.4), kidney...
This redistribution of H, especially at higher exposures, is responsible for the systemic intoxication that involves the cardiovascular, central nervous and immune systems (Fig. 3) [3,22–24]. It also likely plays a role in the findings described in recent Iranian reports that have documented the persistent long-term and chronic effects of H exposure during the Iran-Iraq war that include ocular, dermatological, respiratory, gastrointestinal, haematological, neurological, neuromuscular, immunological and endocrine disruptions (Fig. 3) [25–30].

Although the progression of the injury is well characterized, the mechanism of toxic action of H remains largely unknown. Sulphur mustard is a highly reactive bifunctional alkylation agent, and as such is able to react rapidly with a broad range of cellular constituents and molecular targets. This has resulted in numerous hypotheses being proposed and it has been well recognized as causing the production of reactive nitrogen and oxygen species [31–35], as well as disturbing an array of molecular pathways including; intracellular calcium, anion and pH regulation, poly (ADP-ribose polymerase (PARP) activation, DNA damage and repair, apoptosis induction, inflammation, membrane bound receptors, signalling molecules and extracellular matrices [2,3,11,14,15,36–42]. However, the pathways that ultimately lead to toxicity remain elusive and investigators continue their efforts to define the progression of biochemical/molecular events from exposure to the ultimate expression of overt toxicity.

The oxidative stress and inflammatory processes produced by H in laboratory test models and exposed individuals, have provoked numerous studies investigating the efficacy of the well-known antioxidant N-acetylcysteine (NAC; N-acetyl-L-cysteine, Figs. 2 and 5) against it and it has been suggested that NAC may be a lead candidate for the treatment of this CW agent [5,43]. Its primary mechanism of action is mediated through its ability relative to cysteine to more rapidly pass through biological membranes. Upon subsequent cleavage of the acetyl group to yield free reduced cysteine, it is incorporated into the reactive oxygen species (ROS)-scavenging tripeptide glutathione (GSH; Fig. 5), most especially in those cases where oxidative stress drives cellular GSH depletion (Fig. 6). In addition, NAC is also known to have limited direct antioxidant activity under physiological conditions that is thought to confer modest protective effects, as well as chemical activities not related to GSH that are less understood [44–48]. While the reactive oxygen scavenging activity of NAC has been broadly exploited in clinical settings, notably with its use as an antidote against acetaminophen (paracetamol)-induced hepatotoxicity [49–51], it has become clear that NAC also impacts other pathways either directly or through its GSH-related antioxidant properties, including inflammatory, cell cycle, DNA damage and repair, apoptosis, carcinogenesis and tumour progression, mutagenesis, gene expression, signal transduction, immune modulation, cytoskeleton and mitochondrial function [47,52]. Of interest also are the recent findings that NAC impacts neurotransmission not only through its antioxidant activities, but also through elevation of extracellular glutamate levels via the cystine/glutamate antiporter and subsequent actions on both N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors [46,47,53]. Studies directed at diseases of the nervous system have concluded that there is positive evidence of NAC efficacy in treating a variety of pathologies. However, it has also been noted that the relatively poor membrane permeability of NAC, particularly in penetrating the blood brain barrier may reduce its value as a treatment. Replacement of NAC’s carboxyl group with an amide [54] increases its lipophilicity and allows the resultant N-acetylcysteine amide (NACA, Fig. 5) to more easily cross cell membranes, facilitating transport into the blood brain barrier, mitochondria and other cellular constituents. This would decrease the doses required and perhaps also alleviate some of

---

**Fig. 1.** Chemical structures of sulphur mustard (H), 2-chloroethyl ethyl sulphide (CEES) and mechlorethamine (HN-2).

**Fig. 2.** Sulphur mustard (H) and N-acetylcysteine (NAC) properties. Laboratory-grade H is distilled to a high purity and is a clear oily liquid, compared to the darker munitions-grade H removed from an old artillery shell. N-acetylcysteine can be purchased from chemical companies or as over-the-counter capsule products.

**Sulphur mustard (H)**
- bis(2-chloroethyl) sulphide, mustard gas, yperite, yellow cross liquid
- Oily liquid
- MW = 159.1, MP = 14.4°C
- Garlic-like odor

**N-Acetylcysteine (NAC)**
- Acetylcysteine, N-acetyl-L-cysteine
- White powder
- MW = 163.20, MP = 109-110°C
the side effects noted with NAC. Although no human trials have been conducted with this drug, its reported superior bioavailability and antioxidant activities relative to NAC, show great promise [55–58].

This report consolidates and reviews evidence from both in vitro (Table 1) and in vivo (Table 2) test systems, as well as from clinical trials of H-exposed patients (Table 3), that support NAC as a strong candidate for the safe treatment of H exposure in humans, particularly as a therapeutic against the long-term effects of inhaled H. The data bases PubMed, Defense Technology Information Center (DTIC) and Clinical Trials.gov were searched up to August 2020. The bibliographies of the reports located were then examined for additional relevant publications. Governmental defence reports were not cited if open literature publications were located duplicating the work.

2. NAC and sulphur mustard

2.1. Sulphur mustard tissue culture studies; non-pulmonary (Table 1)

Building on the finding that H forms GSH conjugates [59–61], and the well known fact that thiols were protective against the toxicity of alkylating agents, Walker and Smith [62] reported in 1969 that thiol pre-treatment of mouse L-cells was protective against H. More than two decades later Smith and Gross [63] noted that NAC increased cellular GSH levels in vitro that would react with H and decrease its subsequent toxicity, a finding that was consistent with the increased efficacy of the nitrogen mustard cyclophosphamide against tumours with low GSH levels [64]. Follow-up studies using human peripheral blood lymphocytes showed that a 24 h pre-incubation with 10 mM NAC inhibited the H-induced activation of proteases [65], while a 48 h pre-treatment followed by washout significantly attenuated the toxicity of low H concentrations, but not of high concentrations in these same cells [66]. They concluded that increasing intracellular GSH levels by providing substrates such as NAC for its synthesis may provide a pathway for designing prophylactic strategies to protect against H toxicity. Relatively low NAC concentrations (100 μM) were utilized in studies to compare the efficacy of NAC alone [67] or in combination with other drugs against H toxicity [68]. A 30 or 60 min NAC pre-treatment followed by washout, of 180 μM H-exposed human skin fibroblast HF2FF cells resulted in significant elevations in cellular viability, GSH levels and catalase activity compared to that found in H-only treated cultures.
Further increases in these endpoints were obtained by the inclusion of 2-oxo-thiazolidine-4-carboxylate and acetaminophen. The authors attributed the protection to drug-related increases in GSH levels and catalase activities [68]. In an in vitro model of wound healing, mouse embryoid bodies were utilized to examine the effect of ROS scavengers such as α-linolenic acid (15 ng/ml) and NAC (20 mM) on H-induced toxicity and decreased endothelial tube formation [69]. Both compounds exhibited protective effects, but only transiently. Work examining the effect of NAC co-administration with H in a human keratinocyte cell line (HaCaT) showed that 1–10 mM NAC pre-treatment (with no washout) protected against both H-induced apoptotic and necrotic cell death, but ameliorated inflammatory cytokine release only at low H concentrations. One hour NAC pre-treatments followed by removal before H exposure were only slightly protective, while 1 h post-treatments were ineffective, leading the authors to suggest that most of the protective effects noted in their studies were due to the direct scavenging of H [70]. Stenger and coworkers [71] used aquaporin-transfected HEK293 cells to examine the role of the cation channel TRPA1 in H-induced intracellular calcium (Ca$^{2+}$) flux. They found that H not only activated this channel with concomitant Ca$^{2+}$ increases, but that these responses were reduced by NAC pre-treatment (15 min; 0.1–1.0 mM) in a concentration-dependent manner. No correlations were made with cellular viability in these studies, although it was concluded that chemical scavenging of H by NAC was not the major route through which these effects occurred [71], a conclusion later supported by mass spectrometric studies where NAC and H were co-incubated in either phosphate buffered saline or human serum. In this work, although reaction products of NAC and H were detected and identified, “analyses clearly documented minor reactivity not significantly contributing to reduction of SM concentrations” [72].

2.2. Sulphur mustard animal studies; non-pulmonary (Table 2)

Relatively few studies exist on the use of NAC in animal models not related to H or H simulant pulmonary toxicity. In the mouse ear vesicant model, NAC topical pre-treatments (1 mg in ethanol: 120 min; 10 mg in cream: 15 min) did not prevent the edema and morphological changes induced by 0.16 mg H application to the ear [73]. Intraperitoneal (IP) NAC pre-treatment (10 min) of guinea pigs treated topically with H was slightly effective in reducing skin lesions while post-treatment (5–10 min) was ineffective [74] (cited in Papirmeister and coworkers [3]). N-Acetylcysteine was included in a study examining the protective effects of amifostine and several analogues (DRDE-07, -10, -30, -35) against H and three different nitrogen mustards [75]. Mice were exposed dermally to one LD$_{50}$ of agent and the antidote was administered orally; one dose (NAC; 250 mg/kg) 30 min prior to agent exposure and the remaining doses daily for the next 3 or 7 days. At 4 and 8 days body weights, percent spleen weights, haematological endpoints and biochemistry were assessed. Compared
Table 1  
Effect of N-acetylcysteine against mustard vesicant treatment in tissue culture models.

| Reference/Authors         | Culture Model                  | Treatment and Exposure Time | NAC Treatment     | Agent Effect on Endpoint(s)                          | NAC Effect on Agent-induced Endpoints |
|---------------------------|--------------------------------|----------------------------|-------------------|------------------------------------------------------|---------------------------------------|
| Atkins et al., 2000       | Bovine pulmonary artery endothelial cells | 250, 500 μM H 5-6 hr        | 50 mM NAC         | ↓ Viability                                         | ↑                                    |
|                           |                                |                            | - overnight pre-treatment with washout | ↑ NFκB activation                                     | ↓                                    |
| Balszuweit et al., 2016   | HaCat human skin keratinocyte cell line | 30, 100, 300 μM H 24 hr    | 1-10 M NAC        | ↑ Apoptosis/necrosis                                 | ↓                                    |
|                           |                                |                            | - 1 hr pre-treatment with washout | ↑ Inflammatory cytokines                             | ↓                                    |
|                           |                                |                            | - 1 hr pre-treatment with no washout | Pre-treatment effective in reversing H effects; washout reduced effects |
|                           |                                |                            | - 1 hr post-treatment | Post-treatment not effective                         | ↓                                    |
| Cowan et al., 1992        | Human peripheral blood lymphocytes | 100-500 μM H 16 hr         | 10 M NAC          | ↑ Protease activity                                  | ↓                                    |
| Dabrowska et al., 1996    | Bovine pulmonary artery endothelial cells | 10-1000 μM H 6 hr         | 50 mM NAC         | ↑ Apoptosis                                         | ↓                                    |
|                           |                                |                            | - 20 hr pre-treatment followed by washout | No effect                                            | ↓                                    |
|                           |                                |                            |                      | After treatment                                      | ↓                                    |
|                           |                                |                            |                      | Pre-treatment effective in reversing H effects       | ↓                                    |
|                           |                                |                            |                      | Post-treatment not effective                         | ↓                                    |
|                           |                                |                            |                      | Addition of MESNA did not potentiate                 | ↓                                    |
| Gross et al., 1993        | Human peripheral blood lymphocytes | 10, 30, 300 μM H 48 hr     | 10 mM NAC         | ↓ Viability                                         | ↑                                    |
| Han et al., 2004          | Jurkat T human T lymphocyte cell line | 600 μM CEEs 5-18 hr       | 5 mM NAC          | ↑ 18 hr viability                                   | ↓                                    |
|                           |                                |                            | - 1 hr pre-treatment | ↑ 5 hr ROS                                           | ↓                                    |
|                           |                                |                            |                      | ↑ 7 hr GSH levels                                   | ↓                                    |
|                           |                                |                            |                      | ↑ 5 hr mitochondrial membrane potential              | ↑                                    |
|                           |                                |                            |                      | ↑ 12 hr caspase-3                                    | ↓                                    |
|                           |                                |                            |                      | ↑ Inflammatory cytokines                             | ↓                                    |
| Hoesel et al., 2008       | Alveolar macrophages from rat lung lavage | 50 μM CEEs 4 hr          | 50 μM NAC containing liposomes (concentration not identified) - co-administration | ↓ 24 and 72 hr viability                   | No effect |
|                           |                                |                            |                      | - 30 min pre-treatment                               | ↑                                    |
|                           |                                |                            |                      | ↑ 24 min IL-6                                        | ↓                                    |
|                           |                                |                            |                      | ↑ 30 min EGFR phosphorylation                        | ↓                                    |
|                           |                                |                            |                      | ↑ 30 min ROS                                        | ↓                                    |
|                           |                                |                            |                      | ↑ 24 hr protein carbonylation                        | ↓                                    |
| Jost et al., 2017         | A549 human lung alveolar epithelial cell line | 50 μM H 1, 24, 72 hr      | 2 mM NAC          | ↓ 24 and 72 hr viability No effect                 | ↓                                    |
| Lee and Kagan, 2014       | Primary human bronchial epithelial cells | 200 μM HN-2 15 min – 24 hr | 1-10 M NAC        | ↑ 24 hr IL-6                                        | ↓                                    |
|                           |                                |                            | - 30 min pre-treatment | ↑ 30 min EGFR phosphorylation                       | ↓                                    |
|                           |                                |                            |                      | ↑ 30 min ROS                                        | ↓                                    |
|                           |                                |                            |                      | ↑ 24 hr protein carbonylation                        | ↓                                    |
| Mahmoudabad et al., 2008  | HF2FF human skin fibroblast cell line | 180 μM H 24 hr         | 100 μM NAC        | ↑ 15 min NADPH oxidase                               | ↓                                    |
|                           |                                |                            | - 1 hr pre-treatment followed by washout prior to H exposure 24 hr later | ↑ Viability                              | ↑                                    |
|                           |                                |                            |                      | ↑ GSH levels                                        | ↑                                    |
|                           |                                |                            |                      | ↑ Reactive oxygen species                            | ↓                                    |
| Paramov et al., 2008      | LPS stimulated RAW 264.7 mouse macrophage cell line | 500 μM CEEs 24 hr       | 5, 10 mM NAC      | ↓ NO generation No effect                           | ↑                                    |
|                           |                                |                            | - 5 hr pre-treatment - co-administration | ↑ Thiol levels                                      | ↓                                    |
|                           |                                |                            |                      | 5 hr post-treatment                                  | ↓                                    |
|                           |                                |                            |                      | ↑ Carbonyl protein levels                           | ↓                                    |
|                           |                                |                            |                      | ↑ Viability Maximal with NAC pre-treatment or co-administration Reduced with post-treatment NAC was co-administered for all other endpoints | ↓                                    |

(continued on next page)
| Reference/Autors                | Culture Model                  | Treatment and Exposure Time | NAC Treatment                      | Agent Effect on Endpoint(s)                                                                 | NAC Effect on Agent-induced Endpoints                                      |
|--------------------------------|--------------------------------|----------------------------|-----------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| [98] Rappeneau et al., 2000a   | 16HBE14o- human bronchial epithelial cell line | 500 μM HN-2 3, 24 hr | 1, 10 mM NAC - 24 hr pre-treatment with wash-out prior to HN-2 - co-administration - 1-3 hr post-treatment | ↓ 4 hr metabolic assays ↓ 24 hr viability ↑ 3 hr sulphydryl levels ↑ | (NAC co-administration and post-treatment) NAC co-administration effective only Pre-treatments ineffective |
| [80] Rappeneau et al., 2000b   | 16HBE14o- human bronchial epithelial cell line | 100 μM H 24 hr | 10 mM NAC - co-administration | ↓ Viability | (PR = 1.6) NAC still effective up to 15 min post-H exposure |
| [80] Rappeneau et al., 2000b   | 16HBE14o- human bronchial epithelial cell line | 100 μM HN-2 24 hr | 10 mM NAC - co-administration | ↓ Viability | (PR = 4.9) |
| [68] Saberi and Mahmodabady, 2009 | HF2FF human skin fibroblast cell line | 180 μM H 24 hr | 1.1 mM NAC - co-administered with H for 1 hr, followed by washout | ↓ Viability | ↓ GSH levels ↑ Catalase activity↑ |
| [96] Sabnam and Pal, 2019      | JB6 mouse skin keratinocyte cell line HaCaT human skin keratinocyte cell line | 500 μM CEES 24 hr | 5 mM NAC - 24 hr pre-treatment | ↑ L-cysteine, GSH ↑ Glutathione peroxidase, catalase ↑ 6-phosphofructo-2-kinase ↑ Protein carboxyls ↑ Lipid peroxidation ↑ Viability ↑ Mitochondrial superoxide dismutases ↑ Mitochondrial membrane potential ↑ Inflammatory cytokines ↑ Cell-cell communication ↑ Cell-cell communication ↑ Reactive O₂⁻/N₂O | NAC combined with acetaminophen and OTC slightly increased protection |
| [97] Sabnam et al., 2020       | JB6 mouse skin keratinocyte cell line HaCaT human skin keratinocyte cell line | 500 μM CEES 24 hr | 5 mM NAC - 24 hr pre-treatment | ↑ Mitochondrial superoxide dismutases ↑ Mitochondrial membrane potential ↑ Inflammatory cytokines ↑ Cell-cell communication ↑ Cell-cell communication ↑ Reactive O₂⁻/N₂O ↑ Catalase ↑ Superoxide dismutase ↑ GSH ↑ Akt, Erk1/2/tuberin phosphorylation | |
| [94] Sagar et al., 2014        | LPS stimulated RAW264.7 mouse macrophage cell line | 500 μM CEES 24 hr | 3-10 mM NAC - co-administration | ↑ TRPA1-dependent calcium flux | DNA alkylation |
| [69] Steinritz et al., 2010    | Mouse embryoid bodies | 100 μM H 7 days | 20 mM NAC - 1 hr exposure followed by washout - immediately post-H - 3 days post-H - 6 days post-H | ↓ DNA repair | (only with day 6 NAC treatment) |
| [90] Steinritz et al., 2014    | Mouse endothelial cells | 12.5 μg/ml chlorambucil | 20 mM NAC - 1 hr co-administration | ↓ endothelial cell migration | |
| [71] Stenger et al., 2017      | HEK293-A1-E human epithelial kidney cell line | 15-60 min | 0.1, 0.5, 1.0 mM NAC - 15 min pre-treatment followed by wash-out | ↑ TRPA1-dependent calcium flux | DNA alkylation |

(continued on next page)
Table 1: continued

| Cell Culture Model | Reference/Authors | Treatment and Exposure Time | NAC Treatment | NAC Effect on Agent-induced Endpoints | Table 1 (continued) |
|--------------------|-------------------|-----------------------------|---------------|--------------------------------------|---------------------|
| B16 mouse skin keratinocyte | Tewari-Singh et al., 2011 | 24-48 hr | 0.1-10 mM NAC |↓ Viability No effect (attributed to limited NAC tissue uptake) |↓ Viability No effect (attributed to limited NAC tissue uptake) |
| HaCaT human skin keratinocyte cell line | Weltin et al., 1996 | 7 days | 0, 10 μM NAC |↑ 12 hr apoptosis |↑ 12 hr apoptosis |
| G6 mouse lung slices | Wilde and Upshall, 1994 | 24-48 hr | 2.5 μM NAC |↓ 48 hr mitogenic stimulation |↓ 48 hr mitogenic stimulation |
| 6HBE14o-cells | Rappeneau and co-workers, 2000 | 24 h | -1 hr pre-treatment |↓ 12 hr apoptotic cell death |↓ 12 hr apoptotic cell death |

Abbreviations: CEES: 2-chloroethyl ethyl sulphide; EGFR: epidermal growth factor receptor; H: sulphur mustard; HN-2: bis(2-chloroethyl) methylamine; NAC: -acetylcysteine; MESNA: 2-mercaptoethane sulfonate; OTC: 2-oxo-thiazolidine; ROS: reactive oxygen species.

2.3. Sulphur mustard tissue culture studies; pulmonary (Table 1)

Several research groups have utilized in vivo and in vitro injury models to examine the effect of NAC on H-induced lung toxicity. In a model using early passage bovine pulmonary artery endothelial cells, H was found to produce significant levels of both apoptotic and necrotic cell death. Pre-treatment with high (50 mM) NAC concentrations followed by washout was found to largely eliminate H-induced apoptotic, but not necrotic cell death [78], a finding that was later attributed to NAC-induced increases in GSH synthesis and concomitant reduction of nuclear transcription factor NF-κB activation [79]. Rappeneau and co-workers [80] used human bronchial epithelial 6HBE14o-cells to screen a number of drug combinations to protect against H toxicity. N-Acetylcysteine alone (10 mM) or in combination with doxycycline, N,N'-dimethylthiourea or hexamethylenetetramine provided protection against co-administered H. Further, NAC and NAC + doxycycline were still significantly protective when treatment was delayed up to 15 and 90 min, respectively after H treatment. Human lung alveolar epithelial A549 cells were treated (30 min) with a number of potential protective drugs including 2.0 mM NAC, in the presence or absence of the radioprotective compound mercaptopothesulphonate (MESNA) prior to 50 μM H exposure. Both treatments (NAC, NAC + MESNA) were found to reduce DNA damage induced by H, but did not prevent cytotoxicity [81]. A 30 min pre-treatment of lung slices with 2.5–5.0 mM NAC failed to elicit protection against H in a 24 h lung slice model, although the authors attributed this to the limited capacity of the tissue to take up NAC [82].

2.4. Sulphur mustard animal studies; pulmonary (Table 2)

In a rat model of lung injury animals were administered H vapour (0.35 mg H in 0.1 ml ethanol for 50 min by intratracheal (IT) installation) that produced consistent, non-lethal pathology at 24 h [83]. At the beginning of this exposure, NAC (816 mg/kg) was administered IP and then bronchoalveolar lavage fluid was recovered at 24 h for analysis. The NAC treatment attenuated H-induced changes in lactate dehydrogenase, albumin, total protein, glutathione peroxidase, γ-glutamyl transferase and neutrophil counts, leading this group to conclude that NAC may be useful as a potential treatment for H-induced lung injury [83]. These findings were augmented in additional studies using the same rat model, where nebulized NAC (dose not identified) was administered every 2 h for 12 h after H exposure. Oxygen saturation levels were improved and pulmonary flow obstruction (50%) expiratory
Table 2
Effect of N-acetylcysteine against mustard vesicant treatment in animal models.

| Reference/Authors | Animal Model | Agent Treatment | NAC Treatment | Agent Effects on Endpoints | NAC Effects on Agent-induced Endpoints |
|-------------------|--------------|-----------------|---------------|---------------------------|---------------------------------------|
| [77] Amir et al., 2003 | Rabbit, 2.0-2.5 kg New Zealand White, female | 14C-labeled H onto the central cornea of both eyes - 0.4 μl (0.51 mg) - 1, 6, 24 hr | 50 μl of 10% aqueous NAC/eye - 10 min before and 10 min after H exposure | ↑ 14C-labeled H in eye tissues | ↓ (in all tissues at 1 hr, except for the nictitating membrane, which was increased) ↓ Prostaglandin content - No effect ↑ Aqueous protein - No effect ↑ Glutathione - No effect ↑ Histopathology - Aggravated at 1 hr, small improvements at 6 and 24 hr |
| [83] Anderson et al., 2000 | Rat, 250-300 g Cr:CD SD BBR Male | H vapour (IT) - 0.35 mg H in 0.1 ml EtOH for 50 min - 24 hr assessment | - 816 mg/kg NAC (IP) administered at the beginning of the H exposure | ↓ Bronchiolar lavage: Lactate dehydrogenase - ↓ ↓ ↓ Glutathione peroxidase - ↓ γ-glutamyl transferase - ↑ ≥ 30 % - Neutrophil transferase - ↑ |
| [76] Anari et al., 1988 | Mouse, 25-35 g CD1, female | H (topical) - 0.16 μl of 195 mM H (0.16 mg) applied to the right ear - 24, 48, 72 hr assessments | - 1 g/kg NAC - unknown route - 10 min pre-treatment | ↑ Mortality - Protective ratio = 3.9 |
| [73] Casillas et al., 2000 | Mouse, 25-35 g CD1, female | H vapour (IT) - 0.1 μl applied to the right ear - 0.4 μl (0.51 mg) in 100 μl liposomes (100 nm dia) | - 816 mg/kg NAC (IP) - administered at the beginning of the H exposure | ↑ 1 hr lung 125I leakage - ↓ ↓ ↓ PaO2 - ↑ 125I leakage only - ↓ ↓ ↓ PaO2 - ↑ 125I leakage (liposomal) protective, but not liposomal and hydroxyproline |
| [107] Chatterjee et al., 2004 | Guinea pig, 400 g Hartley, male | CIES (IT) - 0.5-6 mg/kg in 100 μl EtOH - 27 day assessment | - 0.5 g/day NAC in drinking water (PBS) for 30 days starting 3 days prior to CIES infusion | ↑ Hair loss ↓ |
| [103] Das et al., 2003 | Guinea pig, 400 g Hartley, male | CIES (IT) - 0.5-6 mg/kg in 100 μl EtOH - 1 hr to 21 day assessments | - 0.5 mg NAC in PBS by gavage 10 min before CIES - 10 mg NAC in cream; 15 min topical pre-treatment | ↑ Ear edema - No effect ↑ Histopathology - No effect |
| [100] Hoesel et al., 2008 | Rat, 275-325 g Long-Evans, male | CIES (IT) - -6 mg/kg (2 μl/rat in 58 μl EtOH + DPBS) - 340 μl/rat instilled into left lung mainstem bronchus - 4 hr, 3 week assessments | - 3 mg/kg NAC in 100 μl DPBS (125I leakage only) - 3 mg/kg NAC or NAC + α/γ-tocopherol in 100 μl liposomes (100 min dia) - IT instillation immediately after CIES infusion | ↑ 1 hr lung 125I leakage - ↓ ↓ ↓ Pulmonary flow obstruction - ↓ ↓ ↓ Arterial blood pH - ↑ 125I leakage - ↓ ↓ ↓ Pulmonary flow obstruction - ↑ 125I leakage (liposomal) protective, but not liposomal and hydroxyproline |
| [77] Jugg et al., 2013 | Swine, 49-59 kg White (strain not identified), female | H (inhalation) - 100 mg/kg in - 10 min - 12 hr assessment | - 1,200 mg NAC total - 3 mg/kg NAC in 100 μl DPBS (125I leakage only) | ↓ Survival ↑ Neutrophils/protein levels (lavage) - ↓ ↓ ↓ Pulmonary flow obstruction - ↑ 125I leakage (liposomal) protective, but not liposomal and hydroxyproline |
| [84] Keyser et al., 2014 | Rat, 250-300 g Cr:CD SD BBR Male | H vapour (IT) - 0.35 mg H in 0.1 ml ethanol for 50 minutes - 24 hr assessment | NAC, does not identified - nebulized and delivered via inhalation over 5 min - doses delivered at 0.5, 2, 4, 6, 8, 10 hr post-H exposure | ↑ 125I leakage (liposomal) protective, but not liposomal and hydroxyproline |
| [86] Langenberg et al., 1998 | Hairless guinea pig, 400-500 g Crl:AF(HA)BR, male | H vapour (IT) - 5 min nose-only exposures to H vapour - 96 h LCT50 | NAC, does not identified - nebulized and delivered via inhalation over 5 min - doses delivered at 0.5, 2, 4, 6, 8, 10 hr post-H exposure | ↑ Survival ↑ Neutrophils/protein levels (lavage) - ↓ ↓ ↓ Pulmonary flow obstruction - ↑ 125I leakage (liposomal) protective, but not liposomal and hydroxyproline |

(continued on next page)
| Reference/Authors | Animal Model | Agent Treatment | NAC Treatment | Agent Effects on Endpoints | NAC Effects on Agent-induced Endpoints |
|-------------------|--------------|----------------|--------------|---------------------------|---------------------------------------|
| [102] McClintock et al., 2006 | Rat, 275-325g Long-Evans, male | CIES (IT) - 6 mg/kg (2 μl/rat in 58 μl EtOH + DPBS) - 340 μl/rat instilled into left lung mainstem bronchus - 4 hr assessment | - 1.5 mg/kg NAC in 100 μl liposomes (100 nm dia) - IT NAC instillation immediately after CIES - 1.5 mg/kg NAC time course; injected 10 min prior to or 10-180 min after CIES treatment | ↑ Lung <sup>[125]</sup>I leakage ↓ (60%) immediately post-CEES treatment | ↓ (60%) NAC effective when administered 10 min before or up to 60 min after CIES treatment ↓ (55%) GSH + NAC effective up to 90 min post-CEES |
| [101] McClintock et al., 2002 | Rat, 275-325g Long-Evans, male | CIES (IT) - 6 mg/kg (2 μl/rat in 58 μl EtOH + DPBS) - 340 μl/rat instilled into left lung mainstem bronchus - 4 hr assessment | - 5-40 mg/kg NAC (IV) dose response; injected 10 min prior to CIES treatment - 20 mg/kg NAC (IV) time course; injected 30-180 min after CIES treatment | ↑ Lung <sup>[125]</sup>I leakage ↓ Injection of NAC 10 min prior to CIES treatment; optimal at 20 mg/kg NAC (70%) | ↓ Protective effects obtained with 20 mg/kg up to 90 min after CIES treatment (54%) |
| [104] Mukherjee et al., 2009 | Guinea pig, 400g Hartley, male | CIES (IT) - 2 mg/kg in 100 μl EtOH - 2 hr, 30 day assessments | - liposomal (75 mM NAC + α,γ,δ-tocopherols) or α,γ,δ-tocopherols (IT) - 200 μl (1000 nm dia) - 5 or 60 min after CIES treatment | ↑ 2 hr <sup>[125]</sup>I leakage ↓ 5 and 60 min NAC post-treatment | ↓ 30 min lipoperoxidation ↓ 5 min NAC post-treatment ↓ 5 min NAC post-treatment |
| [105] Mukhopadhyay et al., 2009 | Guinea pig, 400g Hartley, male | CIES (IT) - 0.5 mg/kg in 100 μl EtOH - 1 hr, 30 day assessments | - liposomal 75 mM NAC + α,γ,δ-tocopherols (IT) - 200 μl (size not defined) - 5 min after CIES treatment | ↑ Histopathology ↑ MAPK activation (ERK-1, p38, JNK1/2) ↑ AP-1 signaling ↑ D2 cyclinD1, PCNA | Protection at 1 hr and 30 days post-CEES treatment ↓ |
| [106] Mukhopadhyay et al., 2010 | Guinea pig, 400g Hartley, male | CIES (IT) - 0.5 mg/kg in 100 μl EtOH - 1 hr, 30 day assessments | - liposomal 75 mM NAC + α,γ,δ-tocopherols (IT) - 200 μl (size not defined) - 5 min after CIES treatment | ↑ Histopathology ↑ IL-1β, IL-6 ↑ SAF1/MAZ transcription factors | Protection at 1 hr and 30 days post-CEES treatment ↓ ↓ |
| [74] Parsaei et al., 1988 | Guinea pig Strain/weight unknown | H (topical) - unknown dose/time | - NAC (IP) - unknown dose/time - prophylactic or therapeutic | ↑ Dermal lesions ↓ slight decrease with prophylaxis | No effect therapeutically |
| [75] Sharma et al., 2010 | Mouse, 25-30g Swiss, female | H (topical) - 1x LD50 in PEG-300 | - 250 mg/kg NAC (oral) - 30 min before agent and daily for the 3 or 7 subsequent days | ↑ Body weight ↑ Spleen weight ↑ White blood cell count ↑ Lipoperoxidation ↑ DNA fragmentation ↑ Glutathione | No significant effects on any endpoints |
| [75] Sharma et al., 2010 | Mouse, 25-30g Swiss, female | HN-1, HN-2, HN-3 (topical) - 1x LIP<sub>50</sub> in DMSO | - 250 mg/kg NAC (oral) - 30 min before agent and daily for the 3 or 7 subsequent days | ↑ Body weight ↑ White blood cell count ↑ Lipoperoxidation ↑ DNA fragmentation ↑ Glutathione | ↑ HN-1 at 4 days, HN-2 at 8 days ↓ HN-1: reduced GSH at 4 days ↓ HN-2: reduced GSH at 4 days and oxidized GSH at 8 days |

Abbreviations: CEES: 2-chloroethyl ethyl sulphide; DPBS: Dulbecco’s phosphate buffered saline; EtOH: ethanol; H; sulphur mustard; HN-1: (bis(2-chloroethyl) ethylamine); HN-2: bis(2-chloroethyl) methylamine; HN-3(tris(chloroethyl) amine); IP: intraperitoneal; IT: intratracheal; IV: intravenous; LCT<sub>50</sub>: median lethal concentration x time dose; NAC: N-acetylcysteine; NO: nitric oxide; PaO<sub>2</sub>: arterial blood oxygenation; PaCO<sub>2</sub>: arterial blood CO<sub>2</sub>; PCNA: proliferating cell nuclear antigen.
| Reference | Trial Parameters or Case Reports | Inclusion Criteria | NAC Dose Regimen | Outcomes |
|-----------|---------------------------------|-------------------|----------------|----------|
| [119] Abtahi et al., 2016 | Retrospective 5 yr follow-up study NAC-treated bronchiolitis obliterans group compared to asthma and COPD groups - 38 asthma patients - 16 COPD patients - 19 bronchiolitis obliterans patients | H exposure between 1984 and 1987 Patients with documented obstructive pulmonary disease (asthma, COPD, bronchiolitis obliterans) | Asthma and COPD groups: as per existing guidelines with no NAC Bronchiolitis obliterans group: NAC 1200–1800 mg/day orally, inhaled Seretide 125–250/25 (2 puffs BD), azithromycin (250 mg, 3x/week) | 1) Yearly mean FEV1 decline was significantly higher in COPD and bronchiolitis obliterans groups compared to asthma groups 2) No significant difference in yearly mean FEV1 decline between COPD and bronchiolitis obliterans groups 3) The authors conclude that considering the poorer natural history of bronchiolitis obliterans in comparison to COPD, the insignificant differences between the two groups suggest the efficacy of NAC treatment in bronchiolitis obliterans patients |
| [116] Ghanei et al., 2004 | Open-label study No placebo controls 17 patients | H exposure between 1985 and 1988 Patients with chronic bronchitis and bronchiolitis obliterans and not responsive to conventional treatment | NAC 600 mg/day and clarithromycin 500 mg/day orally for 6 months | 1) Cough and sputum production in 10/17 patients at baseline; 10/10 improved 2) FEV1 and FVC were improved 3) No significant change in FEV1/FVC 4) The authors speculate that the results may also be due to the therapeutic effects of clarithromycin |
| [117] Ghanei et al., 2008 | Placebo controlled Double blind, randomized clinical trial 72 NAC patients 72 control patients | H exposure in 1988 Patients with chronic pulmonary disease due to H exposure (bronchiolitis obliterans syndrome class 0) ie. normal pulmonary function | NAC 1200 mg/day in 2 doses orally for 4 months Patients not allowed other drugs 1 month before and during the trial other than salmeterol (50 μg, 2x daily) and fluticasone (250 μg, 2x daily) | 1) Cough, dyspnea and sputum production improved 2) FEV1 and FVC were improved 3) FEV1/FVC was improved 4) The authors noted that a 4 month NAC treatment improved not only symptoms, but also pulmonary function even 18 years after H exposure |
| [118] Shohrati et al., 2008 | Placebo controlled Double blind, randomized clinical trial 72 NAC patients 72 control patients | H exposure in 1988 Patients with chronic pulmonary disease due to H exposure (bronchiolitis obliterans syndrome class 1 and 2) ie. impaired pulmonary function | NAC 1200 mg/day in 3 doses orally for 4 months Patients not allowed other drugs during the trial other than salmeterol (50 μg, 2x daily) and fluticasone (250 μg, 2x daily) | 1) Cough, dyspnea and sputum production improved 2) FEV1 and FVC were improved 3) FEV1/FVC was improved 4) The authors noted that a 4 month NAC treatment improved not only symptoms, but also pulmonary function even 18 years after H exposure |
| [18] Willems, 1989 | Case reports No control groups | H-exposed casualties evacuated to Europe from 1984 to 1986 NAC treatment ~5–17 days after H exposure | 9 patients: aerosolized NAC treatment 26 patients: 150 mg NAC intravenously every 3 h | No conclusions could be made as to the efficacy of NAC treatment due to the absence of control groups, the small group sizes and the large variability in patient histories. However, no note was made of adverse effects due to treatment |

Abbreviations: BO: COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; FEV1: forced expiratory volume (1 s); H: sulphur mustard; NAC: N-acetylcysteine.
flow (EF50)) was reduced in rats 24 h after exposure [84]. These results were further supported in a domestic swine model where NAC was also found to protect against inhaled H [85]. Female white domestic swine (49–59 kg) were anaesthetized and baseline measurements taken. Once stabilized, the animals were exposed to H vapour via the endotracheal tube at a target inhaled dose of 100 μg/kg delivered over 10 min. Drug treatment was administered through the endotracheal tube as an aerosol (1 ml of 200 mg/ml NAC solution of Mucomyst™) at 30 min, 2, 4, 6, 8 and 10 h post-H treatment. Animals were followed for 12 h and sacrificed. Five of six H treated animals survived, compared to eight of eight NAC treated animals, although average histopathological lung injury scores were not significantly different between groups. Animals treated with NAC exhibited improved arterial blood oxygen saturation, pH and bicarbonate levels, as well as fewer neutrophils and lower protein levels in lavage fluid compared to the values obtained in H controls. The authors attributed the beneficial effects to NAC’s antioxidant and mucolytic properties. Unfortunately, this group has not published additional studies investigating longer term outcomes of NAC treatment of H using this powerful animal model. In contrast to the above studies, NAC was not protective against H in hairless guinea pigs. The animals were administered NAC (IP, 5 mMol/kg) 5 min prior to 5 min nose-only H vapour exposures and although pre-treatment increased the 96 h median lethal concentration × time (LCT50) values compared to H-only exposures [LCT50 = 800 mg/min/m³ (H) versus 1285 mg/min/m³ (H + NAC)], they were not statistically significantly different [86]. This study did not make note of any observations at earlier time points.

2.5. Summary of NAC and sulphur mustard

Early studies used tissue culture models and NAC pre-treatment strategies with or without washout, to demonstrate its protective efficacy against H, and to show that in addition to direct scavenging activity, NAC also served as a substrate for increased GSH synthesis. Ensuing in vitro work demonstrated the protective efficacy of NAC in reducing H-induced cytotoxicity, oxidative stress and inflammatory responses in a wide range of culture models. Animal studies using IT infused or inhaled H confirmed the protective value of NAC administered immediately after or 30 min after H exposure. However, although this work showed significant improvements in a variety of lung function and biochemical endpoints, the studies were of only 12–24 h duration. In the one longer term study carried out, although a single IP administration of NAC 5 min prior to H inhalation exposure reduced the 96 h LCT50 in guinea pigs, the values were not statistically different. Unfortunately, the authors did not indicate whether significant but transient protection was present at earlier time points. Although the short-term protective efficacy of NAC against H has been well demonstrated, there is a requirement for additional work examining longer term dosing regimens of NAC by different routes. While 30 day studies have been carried out with the H simulant 2-chloroethyl ethyl sulphide (CEES; see below), it has been shown that there may be some differences in the mechanisms of action between these two chemicals [87] and the long-term persistence of NAC protection against H should also be investigated. Given the well demonstrated effectiveness of NAC in protecting against the toxicity of H in a wide range of tissue culture systems, as well as against inhaled H in animal models, it may also be useful to re-examine its potential as a protectant against cutaneously applied H, especially using the more strongly lipophilic NACA.

3. NAC and sulphur mustard simulants

3.1. Simulants tissue culture studies; non-pulmonary (Table 1)

The protective properties of NAC have also been examined with putative H simulants such as the nitrogen mustards and CEES (Fig. 1). Mechlorethamine (HN-2; bis(2-chloroethyl) ethylamine, Fig. 1) induced apoptotic cell death was reduced in primary C3H murine spleen cultures by the addition of 2.5 mM NAC at the time of treatment, slightly reduced with a 30 min post-treatment, and unaffected with a 60 min post-treatment [88]. In a survey of sulphur containing compounds Valeriote and Grates [89] showed that the colony forming ability of bone marrow cells in a spleen colony assay was enhanced (protection index = 26) when mice were treated with a maximally tolerated dose of NAC (8 mg/mouse, IP) 15 min prior to HN-2 administration (0.3 mg IP), compared to bone marrow cells from animals with no pre-treatment. Early endothelial cells were isolated from mouse embryoid bodies and used to assess the effects of NAC on chlorambucil-induced deficits in wound healing parameters [90]. Co-administration of NAC with chlorambucil was only modestly effective in protecting against its effects, a result that the authors hypothesized may have been due to only transient increases in reactive oxygen and nitrogen species. Pre-incubation of 17 mM NAC for 5 min at room temperature with purified chymotrypsin was shown to completely prevent its inactivation by 4.17 mM chlorambucil, an effect postulated as possibly being a result of the coherent interactions of the thiol and carbonyl groups of NAC with the agent [91]. In studies utilizing both human Jurkat cells and normal human lymphocytes, 5.0 mM NAC pre-treatment prevented the effects of CEES on the accumulation of ROS, intracellular GSH levels and apoptotic cell death markers [92]. In LPS-stimulated murine macrophages (RAW 264.7), 10 mM NAC pre-treatment or co-administration with 500 μM CEES prevented toxicity but had no effect on CEES-induced nitric oxide inhibition inhibition. Delaying the NAC treatment for 5 h yielded much reduced protective effects. Co-administration of 3–10 mM NAC also reversed several CEES-induced oxidative stress parameters [93]. Similar results were found in the same model system where co-administration of 500 μM CEES and 3–10 mM NAC reduced the adverse effects of the simulant on viability, reactive oxygen and nitrogen species, GSH, catalase, superoxide dismutase, Akt phosphorylation, ERK1/2 and tuberin, as well as on markers of DNA repair [94]. Tewari-Singh and coworkers [95] showed that a 25 mM NAC treatment 1 h before or after CEES treatment provided significant protection against cytotoxicity in both JB6 mouse skin and HaCaT human skin cells. The effects of NAC on CEES-induced inflammation, apoptosis and mitochondrial dysfunction were also investigated in these same two cell lines. Pre-incubation of 5 mM NAC attenuated 500 μM CEES-induced oxidative stress, inflammation and apoptosis [96], as well as mitochondrial superoxide dismutases and membrane potential, and cell-cell communication [97].

3.2. Simulants animal studies; non-pulmonary (Table 2)

Mice were utilized in work comparing the efficacy of several amifostine derivatives and NAC against H, as well as the closely related CW nitrogen mustard agents HN-1 (bis(2-chloroethyl) ethylamine), HN-2 and HN-3 (tris(chloroethyl) amine). Oral administration of NAC (see Section 2.2) was largely ineffective against the topical application of these agents compared to the amifostine derivatives [75].

3.3. Simulants tissue culture studies; pulmonary (Table 1)

In studies using the human bronchial epithelial cell line 16HBE14o-, 10 mM NAC was found to reduce HN-2 induced cell death, but only if present during the exposure [98]. Co-administration of NAC with HN-2 in this culture model resulted in a protective ratio of 4.9, significantly better than that obtained for H (1.6) [80]. The authors concluded that in both cases, protection was mainly due to the direct chemical scavenging of NAC with the agents in the culture medium. Primary human bronchial epithelial cells were used to evaluate the role of oxidative stress and epidermal growth factor receptor (EGFR) activation in CEES-induced cytokine secretion. The elevation of interleukin-6, ROS, protein carbonylation, EGFR phosphorylation and NADPH oxidase activation induced by 200 μM CEES was largely eliminated by a 30 min...
pre-incubation with NAC [99]. Primary rat alveolar macrophages from bronchoalveolar lavage were incubated with 500 μM CEES with or without antioxidant liposomes containing NAC (final NAC concentration unclear) for 4 h [100]. Liposomal NAC was shown to significantly reduce the levels of the CEES-induced inflammatory response (CINC-1, IL-1β, IL-6, TNF-α).

3.4. Simulant animal studies; pulmonary (Table 2)

The oxidative stress known to be produced by H and CEES in the lungs and respiratory tract has also resulted in a series of studies examining the effect of NAC against the pulmonary toxicity caused by IT introduction of CEES (6 mg/kg) into the lungs of guinea pigs or rats. McClintock and co-workers [101] showed that intravenous pre-treatment (~10 min) of 20 mg/kg NAC in rats elicited protection against CEES-induced lung toxicity at 4 h (70%), and that treatment was still effective when given up to 90 min after CEES exposure (54% protection). Studies utilizing liposome encapsulated NAC were carried out in an effort to obtain higher and more persistent drug tissue concentrations [102]. In 4 h experiments, rats were exposed IT to ~6.0 mg/kg CEES and IT installation of liposomal NAC was found to be effective in reducing lung damage whether administered 10 min before (60%) or 60 min after (55%) CEES treatment [102]. Similar results were also reported in the same rat model system by Hoesel et al. [100], who showed that liposomal NAC (3 mg) administered IT immediately after CEES treatment was effective in eliminating the short-term effects (4 h; increased lung permeability and elevated pro-inflammatory mediators in bronchoalveolar lavage fluids) induced by ~6.0 mg/kg CEES. However, these studies also showed that similar NAC dosing regimens were ineffective in decreasing CEES-induced fibrosis three weeks after exposure, unless α/γ-tocopherol was also included in the liposomal preparations. This study also included a direct comparison of the protective effects of liposomal NAC encapsulation compared to treatment with NAC in solution (3 mg; Dulbecco’s phosphate buffered saline) against CEES when administered immediately after agent treatment. This work indicated that liposomal NAC reduced the CEES-induced leakage of 125I-albumin from lung parenchyma into the bloodstream at 4 h by 59%, compared to less than 10% for NAC in solution [100].

Similar studies to the rat work were carried out using guinea pigs, a species whose lung function and structure are more similar to that of humans than are rats. In animals exposed IT to 0.5–6 mg/kg CEES, although a single 0.5 g dose of NAC administered via gavage just prior to CEES exposure was ineffective, pre-treatment with 0.5 g NAC/animal/day in the drinking water for 3–30 days protected against 69–76% of the acute (4 h) lung injury and inhibited several associated markers of CEES-induced lung damage [103]. These studies were extended to examine the efficacy of “antioxidant” liposomes comprised of different levels of NAC, GSH, cholesterol, phospholipid and tocopherols against IT CEES-induced lung injury. The IT liposomal treatments were infused at 5 or 60 min after CEES and were effective in reducing several aspects of both short- and long-term lung toxicity in guinea pigs, including increased lung permeability at 2 h, and increased lung lipoperoxidation, hydroxyproline (a measure of fibrosis), and histopathology at 30 days. Optimal protection was obtained when liposomes were comprised of 75 mM NAC, 11 mM α-tocopherol, 11 mM γ-tocopherol and 5 mM δ-tocopherol [104], and this treatment and model system were used in subsequent studies to ascertain whether it could modulate the CEES-induced MAPK/PAK-1 signalling pathway in lung injury [105]. This work showed that although antioxidant liposome treatment was ineffective in reducing the CEES-induced phosphorylation of several members of the MAPK (ERK-1, p38, JNK1/2) family, it did show significant efficacy in decreasing the CEES-induced activation of AP-1 transcription factors, and in decreasing TNF-α, cyclin D1 and proliferating cell nuclear antigen (PCNA) up to 30 days, leading the authors to conclude that the protective effect of antioxidant liposomes against CEES was mediated through control of AP-1 signalling [105].

Further efforts by this group again used this model system to examine the role of the transcription factors serum accelerator factor-1 (SAF-1) and Myc-associated zinc finger protein (MAZ) in CEES-induced inflammation. The antioxidant liposome treatment (5 min post-CEES) significantly blocked the CEES-induced activation of IL-1β and IL-6, as well as SAF-1/MAZ [106], again out to 30 days post-CEES exposure. No NAC-only or liposomal NAC-only treatment groups were included in these studies to show the comparative protective efficacy of NAC or NAC-only encapsulation. As an off-shoot of the above studies, guinea pigs given NAC in their drinking water (0.5 g/day/animal) were found to be less prone to CEES-induced hair loss than IT infused CEES-only exposed animals [107].

N-Acetylcysteine has also been found to be an effective pulmonary protectant in other cases where highly reactive molecular species are produced upon chemical exposure. These include known lung toxicants such as bleomycin [108,109], perfuroisobutene [110], paraquat [111,112] and phosgene [113,114].

3.5. Summary of NAC and sulphur mustard simulants

The protective efficacy of NAC against the H simulants CEES and HN-2 has been demonstrated in several cell culture models where it reversed or reduced the agent-induced deficits on viability, inflammation, oxidative stress and a wide range of additional endpoints. In some systems NAC post-exposure was protective, although this work tended to use relatively low agent concentrations and the protection was reduced with time post-NAC treatment. Several studies have been conducted examining the efficacy of NAC in protecting against the pulmonary injury caused by IT infusion of CEES in both rats and guinea pigs. When NAC was included in the drinking water for 3–30 days prior to CEES exposure, lung damage was reduced out to 21 days in guinea pigs. When encapsulated into liposomes and instilled IT, NAC was only effective in reducing CEES-induced endpoints of lung damage out to 4 h, unless tocopherols were also encapsulated. In these cases, several markers of lung damage were reduced out to 30 days post-CEES exposure. This work demonstrates the potential long-term efficacy of NAC treatment against mustard-induced lung injury when used with liposomal encapsulation, in combination with other drugs, and by different dosing routes.

4. NAC and sulphur mustard casualties (Table 3)

Limited studies exist examining the clinical use of NAC in H-exposed individuals. In a summary of the clinical files of Iranian H casualties evacuated to European hospitals from 1984 to 1986, Willems [18] briefly discussed the use of NAC in patients during their treatment. In 9 patients, NAC was administered as an aerosol primarily for its mucolytic properties, although it was also hoped that it might bind residual free H in the lungs. In addition, 26 patients were also treated via the intravenous infusion of 150 mg NAC every 3 h to bind and inactivate circulating free H in the body. However, no conclusion as to the benefits of these treatments could be made due to the small group sizes and the differences in patient histories. The author also expressed doubts as to the efficacy of a treatment aimed at the detoxification of H when there was no evidence of “toxicologically relevant concentrations of sulphur mustard on the patient or circulating in the blood at the time of arrival at the European clinic several days after exposure” (~5–17 days) [18].

Iranian clinical trials have been carried out examining the effect of NAC on the long-term pulmonary effects in H-exposed veterans of the Iran-Iraq War with positive results [5,115]. In 2004 Ghanei and coworkers [116] reported on a study investigating the effect of daily oral 600 mg NAC and 500 mg clarithromycin treatments on veterans documented as having been exposed to H between 1985 and 1988. These veterans were diagnosed as having bronchiolitis obliterans that was non-responsive to high dose bronchodilator (salmeterol) therapy and inhaled corticosteroid (fluticasone propionate). At six months, in
those patients exhibiting cough and sputum (10/17), all ten exhibited reduced rates of these symptoms. Forced expiratory volume over 1 min (FEV1) was improved in 14 of 17 patients with an overall improvement of 10.6 ± 9.7% (p < 0.001 versus baseline), while forced vital capacity (FVC) was improved in 13 of 17 patients with an overall improvement of 12.9 ± 13.6% (p < 0.001 versus baseline). No placebo, clarithromycin-only, or NAC-only controls were carried out in this study and the authors volunteer that the results may have been due to the clarithromycin treatment. A much larger (144 patients) placebo controlled, double-blind study was conducted by the same group examining the effects of NAC in Iranian veterans “suffering from pulmonary disorders due to a single high dose of sulfur mustard gas during the Iran-Iraq conflict in 1988”, but exhibiting normal pulmonary function (bronchiolitis obliterans syndrome class 0) [117]. Patients received 600 mg NAC or placebo twice daily for four months. No other drugs were allowed one month before or during the trial. However, salmeterol (50 μg twice daily) and fluticasone (250 μg twice daily) were taken by all patients during the study. N-Acetylcysteine was found to be highly effective statistically in reducing dyspnea, cough, and sputum, as well as improving pulmonary function endpoints such as FEV1 and FVC. The authors considered the findings to be remarkable due to the eighteen year gap between H exposure, and the relatively short four month NAC treatment regimen. This same group published a similar study using identical parameters, but this time with inclusion criteria requiring the trial patients to be exhibiting impaired pulmonary function (bronchiolitis obliterans syndrome class 1 and 2) due to the previous 1988 H exposure, and NAC being administered in 600 mg tablets three times daily [118]. Virtually identical conclusions were obtained. However, although these studies appeared to have been run simultaneously by the same group, no comparisons were made between these two trials, even when reviewed by the same authors in later review papers [5,115].

In a retrospective five year follow-up study aimed at assessing the longer term effectiveness of therapy including NAC, Abtahi and coworkers [119] assessed nineteen Iranian veterans suffering from H-induced bronchiolitis obliterans and treated for five years with inhaled Seretide (125–250/25 μg 2 puffs BID), azithromycin (250 mg, three times/week) and NAC (1200–1800 mg/day). When compared against matched chronic obstructive pulmonary disease patient groups (asthma and chronic obstructive pulmonary disease) “treated according to guidelines”, FEV1 decline was similar over the five year period. The authors interpreted this outcome, when considering the poorer prognoses for patients suffering from bronchiolitis obliterans compared to those with COPD, as proof positive of the effectiveness of this long-term treatment regimen.

Although the ability of thioles to bind H has been recognized for many decades, investigations into NAC as a potential H antidote have been carried out primarily after the end of the Iran-Iraq war. Thus, while the few examples of studies using NAC as a treatment in H-exposed casualties are largely positive, they were directed towards the long-term pulmonary effects that occurred many years after exposure. Fortunately, there are relatively few opportunities to investigate the efficacy of drugs against CW agents in humans. However, there exists a significant quantity of work that suggests that NAC or its derivative NACA should have great potential as an early treatment of H-induced injury in humans, either as a scavenger or in preventing the cascades of deleterious events that H has been shown to cause, particularly in the respiratory system. The safety of NAC has been demonstrated in numerous clinical trials (see Section 5.0) and strong consideration should be given to this drug as a first line treatment for H poisoning in the future.

5. NAC in other clinical applications and safety

The relative safety of NAC in humans has been well illustrated not only by its long history of clinical use, but also by the broad range of clinical applications that it is continually being tested for, or applied to. Research on NAC was initiated in the 1960s with reports of its effectiveness as a mucolytic in patients with cystic fibrosis (CF). Its development was the result of efforts to provide reduced thiols to break the disulphide bridges in the glycoprotein matrix of mucus in CF patients. Acetylation of cysteine yielded the much more stable NAC, which was shown to have significant mucolytic activity and clinical applications not only in the treatment of CF, but also in the prophylaxis and therapy of a number of other respiratory diseases [52]. In the 1970s, the ability of NAC to provide sulphhydryl moieties drove the effort to utilize it as a treatment for acetaminophen poisoning. During these studies, its protective role was also shown to include the provision of precursors to replenish GSH levels that had become depleted during phase two metabolism of acetaminophen [46]. The resultant widespread clinical use and success of NAC treatment in acetaminophen poisoning [49-51] has subsequently driven a large body of research investigating its therapeutic potential in a broad range of pathologies and disorders that are thought to be due to oxidative stress and GSH depletion such as bronchitis, doxorubicin-induced cardiotoxicity, acute respiratory distress syndrome, radio-contrast-induced nephropathy, pesticide exposure, heavy metal toxicity, ischemia-reperfusion injury and dermatological conditions [46,47,120,121]. N-acetylcysteine has also recently been proposed as both a preventative and therapeutic agent against COVID-19 due to its abilities to reduce the excessive mucus in HOT, GSH depletion, oxidative stress and inflammation in the lungs that this virus causes [122-127], and several clinical trials are being carried out to assess NAC’s efficacy against this disease [128-131]. Interestingly, it has also been noted “that there are some similarities in the pathogenesis of SARS-CoV-2 and mustard gas in immune system disruption and pulmonary infection” [132], including up-regulation of lung angiotensin-converting enzyme (ACE2), the receptor for SARS-CoV-2. The authors speculate that these commonalities will lead to increased susceptibility and more severe outcomes in Iranian survivors of H exposure to COVID-19 [132].

The mechanistic complexity of NAC has become increasingly obvious and with the revelation that in addition to its antioxidant and GSH stabilizing attributes, it also impacts anti-inflammatory pathways, mitochondrial function, apoptosis and neurogenesis, there has been growing evidence that this drug can also be of utility in treating a host of psychiatric and neurological disorders. Implicit in much of this work have been the discoveries that NAC also impacts neurotransmission not only through facilitation of dopamine release, but also through regulation of NMDA and AMPA due to NAC-induced activation of cysteine/glutamate antiporter activity and subsequent elevations in glutamate levels. Trials using NAC to treat a multitude of neuropsychiatric disorders have been carried out and have yielded positive evidence for its use in the treatment of Alzheimer’s and Parkinson’s diseases, autism, compulsive and grooming disorders, depression, bipolar disorder, schizophrenia, cocaine and cannabis dependence [53,133-138]. In a recent report reviewing NAC safety and efficacy as a protectant against traumatic brain injury (TBI), the authors found “moderate quality of evidence of efficacy and safety of the use of NAC and NACA in preclinical studies” and very limited clinical research in TBI patients [56]. They concluded that the available information warranted further animal work and clinical trials.

Deepmal and coworkers [134] reviewed clinical trials using NAC in neurological and psychiatric diseases, and highlighted the high dosages of this drug that can be tolerated, as well as the potential side effects of this drug. The trials reviewed used daily dosages ranging from 0.6 to 6 g/day with the majority of the studies using 2.0–2.4 g/day. Durations of the trials ranged from 2 days to 60 months, with positive outcomes in all cases. Side effects were rare in these studies, and very few reported were severe enough to necessitate discontinuation of NAC treatment. Gastrointestinal symptoms were the most common side effects and included mild abdominal pain and/or discomfort, nausea, vomiting, heartburn, flatulence, cramps and diarrhea. Neurological side effects included headache and right hand tingling. Isolated
instances of adverse effects also included rash, pruritus, fatigue, dry mouth, muscle pains, insomnia, nasal congestion, runny nose, restlessness, dizziness and irritability [134]. They concluded that given NAC's long track record of safety, tolerability, affordability, availability and positive but still preliminary results, there is a requirement for well designed, larger controlled studies for its use in a variety of different psychological and neurological disorders, a theme echoed in other reviews of NAC in these areas [53,56,133–138].

6. Summary

For over one hundred years, researchers have endeavoured to understand the mechanism of toxic action of H and to develop medical countermeasures against it. Although a great deal has been learned as to how this CW agent disrupts a broad range of cellular, biochemical and molecular pathways, the links between H exposure and toxic effects have as yet to be fully understood. Of the many potential candidate molecules investigated for potential protective efficacy against H, NAC possesses the most robust record both in terms of safety and of efficacy. It is available as an over-the-counter nutritional supplement, and is also considered to be a safe and well tolerated medication for a host of diseases. Although, originally investigated for its direct antioxidant activities and maintenance of intracellular GSH levels, NAC also appears to play a role in an increasingly wide range of cellular pathways. It has been shown to be prophylactically and therapeutically protective against a broad range of drugs/chemicals, including H and H simulants. Notably, studies have repeated the shown efficacy of NAC in decreasing H toxicity in both in vitro and in vivo model systems of lung injury, while Iranian clinical trials have demonstrated the safe and efficacious use of NAC in treating patients suffering the long-term and chronic pulmonary effects of H in veterans of the Iran-Iraq War - up to eighteen years after the initial exposure. The well documented properties of NAC warrant further attention to it as a candidate for additional pre-clinical work, as well as for inclusion in clinical trials to facilitate its regulatory approval as a treatment for the pulmonary effects of H.

Funding

All funding is in-house Defence Research & Development Canada funding.

Declaration of competing interest

None.

References

[1] E.B. Vedder, The Medical Aspects of Chemical Warfare, Williams and Wilkins Company, Baltimore, 1925.
[2] C.M. Pechura, D.P. Rall (Eds.), Veterans at Risk: the Health Effects of Mustard Gas and Lewisite, 1993 Washington, DC.
[3] B. Papirmeister, A.J. Feister, S.J. Robinson, R.D. Ford, Medical Defense against Mustard Gas: Toxic Mechanisms and Pharmacological Implications, CRC Press, Boca Raton, FL, 1991.
[4] F.R. Sidell, J.S. Urbanetti, W.J. Smith, C.G. Hurst, Chapter 7 Vescicants, in: F.R. Sidell, T.E. Takafuji, D.R. Franz (Eds.), Textbook of Military Medicine. Part 1. Warfare, Weaponry and the Casualty. Medical Aspects of Chemical and Biological Warfare, first ed., Office of the Surgeon General, US Army, Falls Church, VA, 1999, pp. 229–246.
[5] Y. Panahi, M. Ghanei, M.M. Hashjin, R. Rezaee, A. Sahebkar, Potential utility of N-acetylcysteine for treating mustard lung, Crit. Rev. Eukaryot. Gene Expr. 27 (2017) e12252, https://doi.org/10.1111/appy.12252.
[6] S. Sezigen, K. Ivelik, M. Ortatatli, M. Almacioglu, M. Demirkasimoglu, R.K. Eyison, Acute hematological complications of sulfur mustard exposure in victims of iranian veterans, Int. Immunopharm. 5 (2005) 1479–1485.
[7] S.M. Razavi, P. Salamati, M. Saghafinia, M. Abdollahi, A review on delayed toxic effects of sulfur mustard in Iranian veterans, DARU J. Pharmaceut. Sci. 20 (2012) 51, https://doi.org/10.1111/j.1748-8058.2012.0231.51.x.
[8] T.W. Sawyer, C.V. Weller, The Medical Aspects of Mustard Gas Poisoning, Mosby, St. Louis, MO, USA, 1919.
mustard-exposed patients: an open-label study, Curr. Ther. Res. 65 (2004) 495–504.
[117] M. Ghanei, M. Shohrati, M. Jafari, S. Ghaderi, F. Alaeeddini, J. Aslani, N-acetyl-
ylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test, Basic Clin. Pharmacol. Toxicol. 103 (2008) 428–432.
[118] M. Shohrati, J. Aslani, M. Esraghi, F. Alaeeddini, M. Ghanei, Therapeutic effects of N-acetyl cysteine on mustard gas exposed patients: evaluating clinical aspect in patients with impaired pulmonary function test, Respir. Med. 102 (2008) 443–448.
[119] H. Abtahi, S. Peiman, M. Foroumandi, E. Salavi, Long term follow-up of sulfur mustard related bronchiolitis obliterans treatment, Acta Med. Iran. 54 (2016) 605-609.
[120] LE. Dhouib, M. Jallouli, A. Anabbi, N. Gharbi, S. Ellafzaa, M.M. Lasram, A mini-review on N-acetylcysteine: an old drug with new approaches, Life Sci. 151 (2016) 359–363.
[121] M. Janecek, L. Moy, A. Riopelle, O. Vetter, J. Reserva, R. Tung, J. Swan, The potential uses of N-acetylcysteine in dermatology: a review, J. Clin. Aesthetic Dermatol. 11 (2018) 20-26.
[122] G. Guglielmetti, M. Quaglia, P.P. Sainaghi, L.M. Castello, R. Vascotto, M. Pirisi, F.D. Corte, G.C. Avazzi, P. Stratta, V. Cantaluppi, “War to the knife” against thromboinflammation to protect endothelial function of COVID-19 patients, Crit. Care 24 (2020) 365, https://doi.org/10.1186/s13054-020-02600-9.
[123] F.L. Poe, J. Corn, N-Acetylcysteine: a potential therapeutic agent for SARS-C0V-2, Med. Hypotheses 143 (2020) 109862, https://doi.org/10.1016/j.mehy.2020.109862.
[124] S. De Flora, R. Balansky, S.L. La Maestra, Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19, Faseb. J. 2021 1–9, https://doi.org/10.1096/fj.2020018070.R.
[125] N. Jaiswal, M. Bhatnagar, H. Shah, N-acetylcysteine: a potential therapeutic agent in COVID-19 infection, Med. Hypotheses 144 (2020) 110133, https://doi.org/10.1016/j.mehy.2020.110133.
[126] R.-M. Jorge-Aarón, M.-P. Rosa-Ester, N-acetylcysteine as a potential treatment for novel coronavirus disease 2019, Future Microbiol. (2020), https://doi.org/10.2127/jmmb-2020-0074.
[127] J. Wu, Tackle the free radicals damage in COVID-19, Nitric Oxide 102 (2020) 39–41.
[128] Memorial Sloan Kettering Cancer Center, A study of N-acetylcysteine in patients with COVID-19 infection, https://clinicaltrials.gov/ct2/show/NCT04375461, (2020).
[129] Cambridge Health Alliance, Efficacy of N-acetylcysteine (NAC) in preventing COVID-19 from progressing to severe disease, https://clinicaltrials.gov/ct2/show/NCT04495672, (2020).
[130] King Saud University, Inflammatory regulation effect of NAC on COVID-19 treatment (INFECT-19), https://clinicaltrials.gov/ct2/show/NCT04455243, (2020).
[131] Obaseni Awolowo University, Antioxidant therapy for COVID-19 study (GSHSOD-COVID), https://clinicaltrials.gov/ct2/show/NCT04466655, (2020).
[132] G. Farnoosh, M. Ghanei, H. Khorramdelazed, G. Alishiri, A.J. Farahani, A. Shahriary, S.R.H. Zijoud, Are Iranian sulfur mustard gas-exposed survivors more vulnerable to SARS-CoV-2? Some similarity in their pathogenesis, Disaster Med. Public Health Prep. (2020), https://doi.org/10.1017/dmp.2020.156.
[133] E. Avedo, A.C. Mendes, M. Berk, E. Brietzke, Systematic review of N-acetylcysteine in the treatment of addictions, Rev. Bras. Psiquiatr. 36 (2014) 168–175.
[134] Deepmala, E.A. McClure, C.D. Gipson, R.J. Malcolm, P.W. Kalivas, K.M. Gray, Systematic review of N-acetylcysteine: an old drug with new approaches, Life Sci. 151 (2016) 359–363.
[135] E.A. McClure, C.D. Gipson, R.J. Malcolm, P.W. Kalivas, K.M. Gray, Potential role of N-acetylcysteine in the treatment of substance use disorders, CNS Drugs 28 (2014) 95–106.
[136] S. Ferrari, M. Galletti, N. Giambalvo, D. Perrone, G. Rioli, A. Minarini, G. Tardiolo, P. Bramanti, E. Mazzon, Overview on the effects of N-acetylcysteine in neurodegenerative diseases, Molecules 23 (2018) 3305, https://doi.org/10.3390/molecules23123305.